{"id": "1364700564186136577", "creation": 1614204944.0, "user_id": "1233901069366771712", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 4, "quote_count": 0}}, "text": "Late to the Game, Novavax Faces an Uphill Battle for #COVID19 #vaccine Success\n\n.@Novavax success depends on manufacturing &amp; licensee deals with Baxter, Serum Inst.of India (SII), Takaeda and Canada's NCR. The pipeline is up to 2B doses\n\n$NVAX $BAX $TAK\n\nhttps://t.co/9CkwjI6JbV", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE"]}